Boehringer Blocked From Making False GSK Inhaler Claims
September 3, 2020
Law360 reported on a Pennsylvania federal judge issuing a preliminary injunction blocking Boehringer Ingelheim Pharmaceuticals from conveying in training materials for its sales representatives false or misleading information about rival GlaxoSmithKline LLC's inhalers for patients with chronic obstructive pulmonary disease. Ballard Spahr Litigation Department members Stephen Kastenberg, Paul Lantieri, Matthew Vahey, and Emilia McKee Vassallo represent GSK.
Read the full article here. (Subscription may be required.)
Subscribe to Ballard Spahr Mailing Lists
Get the latest significant legal alerts, news, webinars, and insights that affect your industry.Subscribe